Promis Neuroscie Stock Price, News & Analysis

ProMIS Neurosciences has begun dosing multiple patients in its Phase 1b PRECISE-AD trial for Alzheimer's disease, marking a significant milestone for the company. The trial is evaluating PMN310, a humanized monoclonal antibody designed to selectively target toxic amyloid-beta oligomers while avoiding binding to monomers and amyloid plaques.

This selective targeting approach potentially differentiates PMN310 from other Alzheimer's treatments on the market or in development, with the goal of delivering a more effective and well-tolerated therapy. The rapid enrollment underscores the urgent unmet need for better Alzheimer's treatments.

The company expects six-month interim results in the first half of 2026, with topline results anticipated in the second half of 2026. Trial investigators highlighted that current Alzheimer's treatments offer only modest efficacy and often come with significant side effects like ARIA.

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. The company's CEO, Neil Warma, will engage in a fireside chat on Wednesday, February 5, 2025, at 1:30 p.m. ET in New York.

ProMIS specializes in developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer's disease, ALS, and multiple system atrophy. The fireside chat will be accessible via live webcast through the Events page on the company's website and will remain available for at least 30 days after the event.

ProMIS Neurosciences (Nasdaq: PMN) shared key achievements from 2024 and outlined plans for 2025 in a shareholder letter. The company successfully completed its Phase 1a clinical trial for PMN310, their lead Alzheimer's disease (AD) treatment, which demonstrated good tolerability and potential target engagement. In July 2024, ProMIS secured up to $122.7 million in financing from healthcare specialty funds to support their ongoing Phase 1b PRECISE-AD clinical trial.

The Phase 1b trial aims to enroll approximately 100 AD patients, with interim data expected in H1 2026 and topline results by year-end 2026. PMN310 targets toxic oligomers while sparing plaque, potentially offering improved safety by reducing ARIA risk. The company's pipeline includes additional candidates PMN267 for ALS/FTD, PMN442 for MSA/Parkinson's, and vaccine candidates PMN400 and PMN311, some of which could enter clinical trials within 12-18 months.

ProMIS Neurosciences has initiated its Phase 1b clinical trial (PRECISE-AD) evaluating PMN310, a humanized IgG1 antibody, for Alzheimer's disease. The trial will assess safety, tolerability, and pharmacokinetics over 12 months in 100 patients with mild cognitive impairment or early AD.

PMN310 is engineered to selectively target toxic oligomers of amyloid-beta while avoiding plaque deposits, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA), a common side effect in existing therapies. The study will be conducted across 22 U.S. sites, with patients receiving monthly doses at three levels (5, 10, 20 mg/kg) or placebo.

Results from the completed Phase 1a study in healthy volunteers showed favorable safety and tolerability. The company expects to share interim data in the first half of 2026.

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, has announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO Neil Warma will engage in a fireside chat on December 3, 2024, at 1:20 p.m. ET in Coral Gables, FL.

The company focuses on developing treatments for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The fireside chat will be accessible via webcast on the company's website and remain available for at least 30 days after the event.

ProMIS Neurosciences announced Q3 2024 financial results and recent highlights. The company reported positive results from its Phase 1a clinical trial of PMN310 for Alzheimer's disease, showing the drug was well-tolerated with monthly dosing and demonstrated potential target engagement. Cash position stood at $21.5 million as of September 30, 2024. The company completed a PIPE financing with $30.3 million upfront and potential for additional $92.4 million from warrant exercises. Q3 showed net income of $9.3 million, primarily due to warrant liability changes. R&D expenses increased to $2.6 million, mainly for PMN310 clinical trials.

ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. CEO Neil Warma will engage in a fireside chat on November 13, 2024, at 10:00 a.m. ET in Boston, MA. The company focuses on targeting toxic misfolded proteins in conditions like Alzheimer's disease, ALS, and multiple system atrophy. A live webcast will be available on the company's website and remain accessible for at least 30 days after the event.

ProMIS Neurosciences presented positive results from its Phase 1a clinical trial of PMN310, an investigational monoclonal antibody targeting toxic amyloid beta oligomers for Alzheimer's disease, at the 17th CTAD Conference. The trial, involving 40 healthy volunteers across five dose cohorts (2.5-40 mg/kg), demonstrated that PMN310 was generally well-tolerated and effectively crossed the blood-brain barrier. The pharmacokinetic data suggests monthly dosing could provide adequate levels for target engagement in AD patients. Based on these results, the company plans to initiate a 12-month Phase 1b trial in 100 patients with mild cognitive impairment due to AD and early AD by year-end 2024.

ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's disease treatment, highlighting its enhanced selectivity for toxic amyloid-beta oligomers (AßO). Key findings show:

1. PMN310 demonstrates little to no interaction with monomers
2. It's minimally impacted by excess monomer competition in binding to toxic oligomers
3. PMN310 doesn't bind to Aß plaque or vascular deposits

These characteristics could potentially reduce the risk of amyloid-related imaging abnormalities (ARIA). ProMIS recently reported positive topline data from the first four cohorts in its Phase 1a trial of PMN310, meeting objectives for tolerability, safety, and pharmacokinetics. The company plans to advance PMN310 into a Phase 1b study in Q4 2024.